🔓
Sign in as a Member to unlock the full view of TAK. · Full hedge fund list, every line-item carveout, cabinet conflicts, and politicians-trading detail.
Become a Member$29.99/mo already a Member? Sign in →
TAK

Takeda Pharmaceutical Company Limited

Sector: healthcareDrug Manufacturers - Specialty & GenericNYSEMarket Cap: $58.95B

Takeda Pharmaceutical is a global healthcare company with its dominant political signal being $71.6M in annual payments to U.S. doctors and teaching hospitals.

Next filing → your inbox
Govt Dependence
0/100
Regulatory Density
95/100
Lobbying Intensity
0/100
Political Signal
NEUTRAL

BusinessWhat TAK does

Takeda Pharmaceutical Company Limited is a global, research-based pharmaceutical company with a primary focus on oncology, rare diseases, neuroscience, gastroenterology, and plasma-derived therapies. Its revenue is generated from the development and commercialization of prescription medicines and vaccines. The company operates a significant U.S. commercial business through its subsidiary, Takeda Pharmaceuticals U.S.A., Inc.

12 months past · 3 months futureTAK activity timeline

$22$18$14 DecJan '26FebMarAprMayJunJulAugSepOctNovDecJan '27Feb ↓ PAST — recorded activity ↑ FUTURE — scheduled markups · pending votes TODAY · Nov 17 $21.43 hi $14.06 lo $21.43 CONGRESS 15 INSIDERS 0 13F FUNDS 30 BILLS 30 Ro Khanna (D) · Purchase · 2026-10-09 D.E. Shaw & Co. · + $67M · 2025-12-31Renaissance Technologies · + $55M · 2026-03-31D.E. Shaw & Co. · - $48M · 2026-03-31Renaissance Technologies · - $42M · 2026-09-30Renaissance Technologies · - $41M · 2026-06-30Renaissance Technologies · - $41M · 2025-12-31Citadel Advisors · + $40M · 2026-03-31D.E. Shaw & Co. · - $33M · 2026-06-30Citadel Advisors · holds $25M · 2025-12-31AQR Capital Management · + $24M · 2026-06-30AQR Capital Management · OPENED $17M · 2026-03-31Citadel Advisors · - $15M · 2026-06-30Two Sigma Investments · + $8M · 2026-06-30Two Sigma Investments · OPENED $6M · 2026-03-31 HR.2001 · passed_one · 2026-07-21 MARKUP · Senate Veterans' Affairs · 2026-11-18MARKUP · Senate Finance · 2026-11-18MARKUP · Senate Health, Education, Labor, and Pensions · 2026-11-18MARKUP · Senate Budget · 2026-11-18MARKUP · Senate Veterans' Affairs · 2026-11-18
Congress
buy sell
Insider · Form 4
open-market buy
Hedge fund · 13F
opened + added − trimmed closed holds
Bills
past action (this ticker) upcoming markup (sector) ★ carveout (this ticker)
249 trading days · 1 congressional trades shown · 0 insider buys · 14 13F filings · 1 past bill actions · 5 upcoming markups

Lifetime Government AwardsTAK federal contracts by year

$551K
total awarded · 2026–2026
1
contracts on file
2026
peak year ($551K)
$551K $275K 2026: $551K across 1 contract (peak year) $551K 2026
Top contracts by award amount
$551K Department of Justice 2026-04-01 FY26 PHARMACEUTICALS TAKEDA APRIL-SEPTEMBER
1 years · 1 contracts

Smart Money · 13F HoldingsHedge funds holding TAK

$122.9M
Total TAK held by tracked 13F funds
6
Funds with TAK positions
+1
Funds opened this quarter
Renaissance Technologies $42M -11% 1 overlap 2026-09-30
D.E. Shaw & Co. $33M -21% 2026-06-30
AQR Capital Management $24M +71% 2026-06-30
Citadel Advisors $15M -57% 2026-06-30
Two Sigma Investments $8M +56% 2026-06-30
Point72 Asset Management $1M opened 2026-06-30

Politicians Trading TAKMembers of Congress with recent TAK positions

1 politicians traded TAK across 1 disclosed transactions totaling $8K (last 730 days). Greed score = composite of trade frequency, volume & recency across the politician's entire history (not just TAK). 0-30 LOW · 30-60 MID · 60+ HIGH.

Congressional TradesWho in Congress is trading TAK

2026-10-09 Ro Khanna D-California · house Purchase $1,001 - $15,000
2023-08-29 Virginia Foxx R-North Carolina · house sale $15,001 - $50,000
2023-08-29 Virginia Foxx R-North Carolina · house Sale $15,001 - $50,000
2023-07-10 Daniel S. Goldman D-New York · house sale $15,001 - $50,000
2023-07-10 Daniel S. Goldman D-New York · house Sale $15,001 - $50,000
2023-02-16 Virginia Foxx R-North Carolina · house purchase $1,001 - $15,000
2023-02-16 Virginia Foxx R-North Carolina · house Purchase $1,001 - $15,000
2022-11-01 Virginia Foxx R-North Carolina · house purchase $1,001 - $15,000
2022-11-01 Virginia Foxx R-North Carolina · house Purchase $1,001 - $15,000
2019-09-11 Greg Gianforte R-Montana · house sale $1,001 - $15,000
2019-09-11 Greg Gianforte R-Montana · house Sale $1,001 - $15,000
2019-03-25 Van Taylor R-TX · house sale $15,001 - $50,000
15+ trades on file · most recent 2026-11-05

Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock

Stock awards & option exercises

25
stock awards · $10.3M market value
2026-07-01 Plump Andrew Stewart President, R&D AWARD 125,390 sh $2.0M
2026-07-01 Kim Julie So-Young President and CEO AWARD 50,434 sh $804K
2026-07-01 Pacheco Rhonda Janice President, U.S. Business Unit AWARD 50,156 sh $800K
2026-07-01 Platford Giles Richard President, IBU AWARD 49,558 sh $790K
2026-07-01 Duprey Lauren Rusckowski Chief Transformation Officer AWARD 45,140 sh $720K
2026-07-01 Furney Natalie Anne Marie Global General Counsel AWARD 43,886 sh $700K
2026-07-01 Bitetti Teresa Marie President, OBU AWARD 43,886 sh $700K
2026-07-01 Ricci Gabriele Chief Data & Tech. Officer AWARD 37,616 sh $600K
For TAK, executives receive stock primarily as compensation rather than via open-market purchases — typical for established large-cap firms.

Bills Affecting TAKLive legislation impacting this stock

Political ProfileWhere TAK sits in Washington

[object Object]

STRUCTURAL: High regulatory density from healthcare sector legislation (8 bills with impact_ratio 0.0001) and significant Sunshine Act reporting exposure ($71.6M in 2024 doctor payments). EVIDENTIARY: No evidentiary signals present; zero federal contracts (`get_government_precedent.federal_contracts_summary` is null), zero lobbying spend, zero insider buys (`get_corporate_insider_signal.total_buys` is 0), and zero congressional trades. Net: Structural regulatory risk is not offset by any positive evidentiary alignment.

Regulatory ExposureThreats & opportunities

Regulatory threats

  • Heightened scrutiny of physician payments under the Sunshine Act
    Centers for Medicare & Medicaid Services (CMS)
    "`get_political_influence.doctor_payments` shows $71.6M in 2024 payments, creating regulatory and reputational exposure."

Regulatory opportunities

  • No specific regulatory opportunities flagged.
Member intelligence layer

Live signals + predictions for TAK — for Founders

The free page above gives you the public record. Members see the real-time intelligence layer on top of it:

Become a Founder · $29.99/mo Locked rate forever · cancel anytime

Frequently AskedAbout TAK & political exposure

Does Takeda Pharmaceutical Company Limited (TAK) hold federal contracts?
Yes. Takeda Pharmaceutical Company Limited has 1 federal contract awards totaling $550,609, primarily from agencies including Department of Justice. See full contract list and amounts on this page.
Has Congress traded TAK stock?
15 congressional trades by 5 unique members of Congress, most recently on 2026-10-09. See the Congressional Trading panel for politician-by-politician breakdown.
What is TAK political risk profile?
Government dependence: 0/100. Lobbying intensity: 0/100. Political signal: neutral. Donor party split: R 0% / D 0%.
How does GovGreed track TAK political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. TAK data is updated daily from these official federal sources.